Imaging Markers of Progression in Parkinson's Disease

Parkinson's disease (PD) is the second‐most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD.

• Publication year

  2018

• Venue

  Movement Disorders Clinical Practice

• Publication date

  2018-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mdc3.12673PMID 30637278PMCID PMC6277366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Overlapping and distinct neural metabolic patterns related to impulsivity and hypomania in Parkinson’s disease

  2019cited by this paper
• The cortical cholinergic system contributes to the top‐down control of distraction: Evidence from patients with Parkinson's disease

  2019cited by this paper
• Compensatory dopaminergic‐cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease

  2019cited by this paper
• Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder.

  2018cited by this paper
• The functional network signature of heterogeneity in freezing of gait

  2018cited by this paper
• [18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP

  2018cited by this paper
• Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study

  2018cited by this paper
• Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy

  2018cited by this paper
• Network imaging biomarkers: insights and clinical applications in Parkinson's disease.

  2018cited by this paper
• Progression of tremor in early stages of Parkinson’s disease: a clinical and neuroimaging study

  2018cited by this paper
• [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy

  2017cited by this paper
• Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease

  2017cited by this paper
• 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy

  2017cited by this paper
• Abnormal intrinsic brain functional network dynamics in Parkinson’s disease

  2017cited by this paper
• Thalamic cholinergic innervation makes a specific bottom‐up contribution to signal detection: Evidence from Parkinson’s disease patients with defined cholinergic losses

  2017cited by this paper
• Decreased intestinal acetylcholinesterase in early Parkinson disease

  2017cited by this paper
• Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis.

  2017cited by this paper
• Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER

  2017cited by this paper
• Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?

  2017cited by this paper
• Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes

  2017cited by this paper
• Positron emission tomography imaging of tau pathology in progressive supranuclear palsy

  2017cited by this paper
• Elevated in vivo [18F]‐AV‐1451 uptake in a patient with progressive supranuclear palsy

  2017cited by this paper
• Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.

  2017cited by this paper
• Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease

  2017cited by this paper
• Resting-state brain networks in patients with Parkinson's disease and impulse control disorders.

  2017cited by this paper
• Microglial activation in Parkinson’s disease using [18F]-FEPPA

  2017cited by this paper
• Progression marker of Parkinson’s disease: a 4-year multi-site imaging study

  2017cited by this paper
• Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility‐weighted imaging in idiopathic rapid eye movement sleep behavior disorder

  2016cited by this paper
• Cholinergic and perfusion brain networks in Parkinson disease dementia

  2016cited by this paper
• Visual dysfunction in Parkinson’s disease

  2016cited by this paper
• Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study

  2016cited by this paper
• Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson’s Disease

  2016cited by this paper
• Age at onset and Parkinson disease phenotype

  2016cited by this paper
• ReSPonD ) : a randomised , double-blind , placebo-controlled , phase 2 trial

  2016cited by this paper
• Serotonin-to-dopamine transporter ratios in Parkinson disease

  2016cited by this paper
• Serotonin transporter in Parkinson's disease: A meta‐analysis of positron emission tomography studies

  2016cited by this paper
• Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment

  2016cited by this paper
• In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.

  2016cited by this paper
• Free-water imaging in Parkinson's disease and atypical parkinsonism.

  2016cited by this paper
• Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes

  2016cited by this paper
• In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET

  2016cited by this paper
• Striatal and Cortical β‐Amyloidopathy and Cognition in Parkinson's Disease

  2016cited by this paper
• Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study.

  2015cited by this paper
• Longitudinal changes in free-water within the substantia nigra of Parkinson's disease.

  2015cited by this paper
• Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers

  2015cited by this paper
• Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy

  2015cited by this paper
• Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease

  2015cited by this paper
• Effects of levodopa on regional cerebral metabolism and blood flow

  2015cited by this paper
• Abnormal connectivity between the default mode and the visual system underlies the manifestation of visual hallucinations in Parkinson’s disease: a task-based fMRI study

  2015cited by this paper
• The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study.

  2015influential reference
• Putaminal serotonergic innervation

  2015cited by this paper
• Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.

  2015influential reference
• Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson’s Disease

  2015cited by this paper
• Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.

  2015cited by this paper
• Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects.

  2015influential reference
• The ongoing pursuit of neuroprotective therapies in Parkinson disease

  2015cited by this paper
• Cognitive impairment and resting‐state network connectivity in Parkinson's disease

  2015cited by this paper
• A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role?

  2015cited by this paper
• Functional connectome assessed using graph theory in drug-naive Parkinson’s disease

  2015cited by this paper
• Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits

  2015cited by this paper
• Single versus multiple impulse control disorders in Parkinson’s disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release

  2015influential reference
• Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease

  2015cited by this paper
• Extra‐nigral pathological conditions are common in Parkinson's disease with freezing of gait: An in vivo positron emission tomography study

  2014cited by this paper
• Neuroimaging in Parkinson disease: from research setting to clinical practice

  2014cited by this paper
• Tricks of the mind: Visual hallucinations as disorders of attention.

  2014cited by this paper
• Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.

  2014cited by this paper
• Uncovering the role of the insula in non-motor symptoms of Parkinson's disease.

  2014cited by this paper
• The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease

  2014cited by this paper
• I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging

  2014cited by this paper
• Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease

  2014cited by this paper
• Resting-state fMRI sheds light on neural substrates of cognitive decline in Parkinson disease

  2014cited by this paper
• Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

  2014cited by this paper
• Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases

  2013cited by this paper
• The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

  2013cited by this paper
• A Journal of Neurology

  2013cited by this paper
• Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.

  2013cited by this paper
• Leveraging the cortical cholinergic system to enhance attention.

  2013cited by this paper
• Gait speed in Parkinson disease correlates with cholinergic degeneration

  2013cited by this paper
• Visualization of nigrosome 1 and its loss in PD

  2013influential reference
• Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia

  2012cited by this paper
• Default-mode network connectivity in cognitively unimpaired patients with Parkinson disease

  2012cited by this paper
• Investigating visual misperceptions in Parkinson's disease: A novel behavioral paradigm

  2012cited by this paper
• Interaction between aging and neurodegeneration in amyotrophic lateral sclerosis.

  2012cited by this paper
• Heterogeneity of Cholinergic Denervation in Parkinson's Disease without Dementia

  2012cited by this paper
• Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo.

  2012influential reference
• Translocator Protein (18 kDa) Polymorphism (rs6971) Explains in-vivo Brain Binding Affinity of the PET Radioligand [18F]-FEPPA

  2012cited by this paper
• The default mode network integrity in patients with Parkinson’s disease is levodopa equivalent dose-dependent

  2012cited by this paper
• Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

  2012cited by this paper
• [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism

  2012cited by this paper
• Resting state fMRI in Alzheimer's disease: beyond the default mode network.

  2012cited by this paper
• Cholinergic modulation of cognitive processing: insights drawn from computational models

  2012cited by this paper
• Graft‐induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio

  2011cited by this paper
• The interplay of cholinergic function, attention, and falls in Parkinson's disease

  2011cited by this paper
• Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.

  2011cited by this paper
• Large-scale brain networks and psychopathology: a unifying triple network model.

  2011cited by this paper
• Amyloid imaging of Lewy body‐associated disorders

  2010cited by this paper
• Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease

  2010cited by this paper
• Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease

  2010cited by this paper
• Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD

  2010cited by this paper

• Neuroimaging-based data-driven subtypes of spatiotemporal atrophy due to Parkinson’s disease

  2025cites this paper
• Immediate modulatory effects of transcutaneous vagus nerve stimulation on patients with Parkinson’s disease: a crossover self-controlled fMRI study

  2024cites this paper
• Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease

  2024cites this paper
• Automated Parkinson's Disease Detection: A Review of Techniques, Datasets, Modalities, and Open Challenges

  2024cites this paper
• Structural and Molecular Imaging for Clinically Uncertain Parkinsonism

  2023cites this paper
• The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms.

  2023cites this paper
• Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research

  2023cites this paper
• Glymphatic Magnetic Resonance Imaging: Part II—Applications in Sleep and Neurodegenerative Diseases

  2023cites this paper
• Motor networks, but also non-motor networks predict motor signs in Parkinson’s disease

  2023cites this paper
• Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?

  2023cites this paper
• Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson Disease

  2022cites this paper
• Metabolic imaging and plasticity.

  2022cites this paper
• Imaging in Huntington’s

  2021cites this paper
• Clinical Trials for Disease-Modifying Agents in Parkinson’s Disease

  2021cites this paper
• MRI characterization of rat brain aging at structural and functional level: Clues for translational applications.

  2021cites this paper
• Contributions of sex, depression, and cognition on brain connectivity dynamics in Parkinson’s disease

  2021cites this paper
• Clinical Trials In Parkinson's Disease

  2021cites this paper
• Contributions of sex, depression, and cognition on brain connectivity dynamics in Parkinson’s disease

  2021cites this paper
• Nicotinamide riboside alleviates Parkinson’s disease symptoms but downregulates dopamine metabolism upon lactacystin-induced proteostasis failure

  2021cites this paper
• Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis

  2021cites this paper
• Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.

  2020cites this paper
• for Disease-Modifying Agents in Parkinson’s

  2020cites this paper
• Cortical thickness in Parkinson disease

  2020cites this paper
• Modern Brainstem MRI Techniques for the Diagnosis of Parkinson's Disease and Parkinsonisms

  2020cites this paper
• Lateralized Connectivity between Globus Pallidus and Motor Cortex is Associated with Freezing of Gait in Parkinson's Disease.

  2020cites this paper
• Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

  2019cites this paper
• Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease.

  2019cites this paper
• Radiomics approach in the neurodegenerative brain

  2019cites this paper